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EFFECTIVE GRAFT-VERSUS-LEUKEMIA RESPONSES TO DONOR LYMPHO-
CYTE INFUSION ARE ASSOCIATED WITH PREEXISTING CD8 + T CELL
MARROW INFILTRATES
Hainz, U.1, Pozdnyakova, O.2, Aldridge, J.3, Kim, H.3, Canning, C.M.1,
Soiffer, R.J.4, Ritz, J.1,4, Alyea, E.P.4, Wu, C.J.1,4 1 Dana-Farber Cancer
Institute, Boston, MA; 2 Brigham and Women’s Hospital, Boston, MA;
3 Dana-Farber Cancer Institute, Boston, MA; 4 Dana-Farber Cancer
Institute, Boston, MA
Donor lymphocyte infusion is a highly effective treatment for
relapsed CML after allogeneic hematopoietic stem cell transplant
(HSCT), but predictors of response are unknown. In CML, mar-
row is the primary site of disease as well as a reservoir of high-
avidity antigen-specific memory B and T cells that can recognize
tumor antigens. We therefore examined serial bone marrow biop-
sies obtained before and after DLI for evidence of immune cell re-
sponse from 31 patients with relapsed CML following allogeneic
HSCT at our center between 1994-2001. All patients received
CD4 +DLI (3-10  107 CD4+ cells/kg) from the original stem
cell donor. Twenty-four patients achieved complete cytogenetic
remission following DLI, while 7 patients were non-responders.
Marrow biopsies, collected prior to DLI, within the first 2-3
months following DLI and approximately 1 year after DLI were
examined for cells expressing CD3, CD8, CD20 and CD138 by
immunohistochemistry, and were also scored for cellularity. DLI
responders demonstrated an increase in CD3 + T cells following
DLI compared to pre DLI (p5 0.07), while no increase was ob-
served among DLI non-responders. This infiltrate, appearing fol-
lowing DLI, consisted almost entirely of CD8 + T cells.
Significant changes in cells expressing CD20, CD138 were not ob-
served. Examination of the pre-treatment marrow revealed that in-
filtration by leukemia-reactive T cells was closely associated with
response to DLI. We detected a significantly increased percentage
of marrow-infiltrative CD3 + CD8 + T cells in pre-treatment mar-
row biopsies of responders (median 8%, range 2-20) compared to
non-responders (2.5%, range 1-2.5), p5 0.013. Degree of marrow
cellularity prior to DLI was also highly predictive of outcome.
While responders demonstrated a 50% median cellularity prior
to DLI, non-responders demonstrated more advanced relapse
with median cellularity at the time of DLI of 93% (p5 0.004).
Of the responders, we observed that 3 patients had 70% or greater
marrow cellularity, but also had 5% CD3 + CD8 + T cell infiltra-
tion, while all non-responders demonstrated \5% T cells, sug-
gesting that T cells can overcome advanced tumor cellularity in
some cases. These studies suggest that the presence of T cell infil-
trates in the marrow microenvironment is a significant predictor of
DLI response. This also implies that the effectiveness of DLI may
be mediated in part through the enhancement of pre-existing
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ROMEDEPSIN (RM), A HDACI, SIGNIFICANTLY INCREASES THE EXPRES-
SION OF NKG2D LIGANDS, MIC A/B, IN LEUKEMIA/LYMPHOMA CELLS
(LL), IN PART THROUGH THE GLYCOGEN SYNTHASE KINASE-3 (GSK-
3) PATHWAY, RESULTING IN ENHANCED NK CYTOTOXICITY: TRANSLA-
TIONAL APPROACH FOR ADOPTIVE NK CELL IMMUNOTHERAPY
Satwani, P.1, Saha, A.1, Bavishi, S.1, Zhao, F.1, Ayello, J.1, van de
Ven, C.1, Cairo, M.S.1,2,3 1 Columbia University, New York, NY; 2 Co-
lumbia University, New York, NY; 3 Columbia University, New York, NY
Introduction: Natural killer (NK) cells recognize malignant cells
through the tumor-associated expression of NKG2D-ligands, in-
cluding MIC A/B. However, tumor cells may shed MIC A/B and es-
cape immuno- surveillance. Glycogen synthase kinase-3 (GSK-3),
a constitutively active serine-threonine kinase with numerous func-
tions including regulation of cellular differentiation, stress and apo-
ptosis, also an important regulatory enzyme in the expression ofMIC
A/B in response to RM (Skov et al, Cancer Res, 2005).
Objective: To determine the expression of MIC A/B in response to
RM in various leukemia and lymphoma cells (LL), its influence on
NK cell mediated cytotoxicity and to investigate the role of the
GSK-3 pathway in the regulation of expression of MIC A/B in re-
sponse to RM.Methods: LL cells (106/ml, RS 4:11 [MLL-ALL], REH [pre-B cell
ALL], Jurkat [T-cell ALL], Toledo [DLBCL], Ramos [Burkitt’s
Lymphoma]) were exposed to RM (10 ng/mL) for 24 hours, followed
by FACS staining with PE-conjugated anti-MIC A/B. Peripheral
blood NK cells were isolated via magnetic separation followed by
IL-2 activation. Cytotoxicity assays (europium assay) were
performed at effector:target (E:T) ratio of 5-10:1. LL cells were
also pre-treated for 1 hour with 100 mM lithium chloride (LiCl),
a potent inhibitor of GSK-3 activity. Blocking studies were also per-
formed with anti-NKG2D antibodies.
Results: MIC A/B expression significantly increased in LL cells in
response to RM ([RS4:11 0.2% vs 82%, p\ 0.0001], [REH 0.2%
vs 46%, p5 0.0003], [Jurkat 1.12% vs 85%, p\ 0.0001], [Toledo
0.5% vs 15.8%, p5 0.0001], [Ramos 0.57% vs 67%, p5 0.0003]).
Enhanced expression of MIC A/B in response to RM was inhibited
when LL cells are pre-treated with LiCl (Jurkat [RM vs RM +LiCl]
85% vs 18%, p\0.0001; RS 4:11 [RM vs RM +LiCl] 82% vs 5%,
p\0.0001; Ramos [RM vs RM +LiCl] 67% vs 35%, p\0.0001).
Cytotoxicity assays revealed significant increases in-vitro cytotoxicty
in RS 4:11, Ramos and REH cells at E:T ratio of 5-10:1 (Table-1).
NKG2D receptor-blocking resulted in significant decrease in NK
cell mediated cytotoxicity in REH (p\0.03) and Ramos cells
(p\0.001). In-vivo experiments are underway.
Conclusion: Expression of MICA/B in LL cells is significantly in-
creased by RM leading to enhanced susceptibility for NKG2D-
MIC A/B mediated cytotoxicity by NK cells. Furthermore, up-reg-
ulation of MICA/B in LL cells secondary to RM exposure is in part
regulated by the GSK-3 signal transduction pathway.416
PRELIMINARY RESULTS OF A PHASE II TRIAL OFMONTELUKAST FOR THE
TREATMENT OF BRONCHIOLITIS OBLITERANS SYNDROME AFTER HSCT
Williams, K.M.1, Pavletic, S.Z.1, Hakim, F.T.1, Mitchell, S.A.2, Gea-
Banacloche, J.C.1, Comis, L.E.2, Cowen, E.W.3, Baird, K.4, Louie, A.5,
Shelhamer, J.H.6, Blacklock-Schuver, B.A.J.1, Avila, D.1,
Carpenter, A.1, Gress, R.E.1 1 National Cancer Institute, NIH, Bethesda,
MD; 2 National Institutes of Health, Bethesda, MD; 3 National InstituteS
of Health, Bethesda, MD; 4 National Cancer Institute, NIH, Bethesda,
MD; 5 NIH Clinical Center, Bethesda, MD; 6 NIH Clinical Center,
Bethesda, MD
Bronchiolitis obliterans syndrome (BOS) after allogeneic HSCT
is a severe manifestation of cGVHD. Current treatments yield
poor and transient responses. Although the pathogenesis of BOS
after HSCT is unknown, a similar disease, BOS after lung trans-
plant is associated with elevated leukotriene levels. We present
Poster Session II S311preliminary results from an IRB-approved prospective, open label,
phase II trial to test the efficacy of montelukast, a leukotriene in-
hibitor, for the treatment of BOS after HSCT. BOS diagnostic
criteria included: FEV1\75%, FEV1/VC\0.7 or air trapping
on CT and RV. 120% or RV/TLC. 120% in the absence of in-
fection and presence of another cGVHD manifestation. Eleven
patients have enrolled to date. One withdrew prior to medication
initiation and 9/10 are currently on study medication (10 mg mon-
telukast po nightly). Patient characteristics include age range
15-60 years, 7/11 female, baseline FEV1 range from 33 to 71%
predicted, and 3/11 patients requiring oxygen supplementation.
Sixty-four % (7/11) have reached the primary endpoint (6 months
of study drug). FEV1 increased by 6-10% predicted in 3 patients,
remained stable in 3, and declined by less than 15% in 1. Slope of
the FEV1 value generated as linear regression of FEV1 volume vs.
days post-transplant revealed: 5/7 increase in slope, 2/7 decrease
in slope from pre-study FEV1 values. Three patients had immu-
nosuppression reduced during this time period with complete ces-
sation of tacrolimus in 1, cessation of steroids in 1, and decreased
tacrolimus in 1(including 2 with stable FEV1 and 1 with increase
in FEV1); 1 patient had an increase in steroid dose less than 1 mg/
kg/day. Two patients had worsening of other cGVHD manifesta-
tions on study, including a skin flare that resolved without increas-
ing systemic therapy (1) and gastrointestinal cGVHD flare that
improved with increased steroids including local therapy (1). Mon-
telukast was well-tolerated with one grade II attributable adverse
event (insomnia) during the six-month collection period.
Improvements were also noted in oral mucosa cGVHD manifesta-
tions in 3/7 and liver in 2/7. These preliminary findings suggest
that montelukast may have a role in the therapy of BOS after
allogeneic HSCT.417
POMALIDOMIDE (POM) IN ADVANCED CORTICOSTEROID-RESISTANT
CHRONIC GRAFT-VERSUS-HOST DISEASE (CGVHD)
Pusic, I.1, DiPersio, J.F.1, Goran, S.L.1, Romvari, E.M.1, Bauer, S.L.1,
Comer, H.S.1, Abboud, C.N.1, Cashen, A.F.1, Gale, R.P.2 1 Washington
University School of Medicine, Siteman Cancer Center, St. Louis, MO;
2 Celgene Corporation, Summit, NJ
Background: Thalidomide is active in cGVHD, but with trouble-
some side effects such as neutropenia, neuropathy and somnolence.
POM is a member of the new class of immune-modulating drugs
(IMiD) .100-fold more potent than thalidomide in inhibiting
production of TNFa and increasing Th1-cells. We assessed effi-
cacy and safety of POM in people with corticosteroid-resistant
cGVHD.
Methods: Subjects had to have moderate (N5 2) or severe
(N5 6) cGVHD (NIH criteria), and failed prednisone (0.5 mg/
kg/d for .8 w) and/or 2nd-line immune-suppression. No ECP
in the preceding 3 m or new therapy in the preceding 1 m was al-
lowed. POM was given by mouth at a starting dose of 3 mg/d with
dose-reduction to 2, 1, and 0.5 mg/d for intolerance or adverse
events. Subjects were evaluated for response every 3 m. Responses
were assessed based upon changes in signs or symptoms of each
organ system and overall response was than determined using
NIH Criteria.
Results: 8 subjects are enrolled so far. Median time posttransplant is
2.9 y (1.5-6 y), median time since diagnosis of cGVHD is 1.8 y (1-4.5
y), 4 subjects received related- and 4 unrelated-allotransplants; 5 had
prior acute GVHD. Median N of prior systemic cGVHD therapies
was 3 (2-5). Affected organs included skin (N5 8), mouth (N5 8),
eye (N5 7), GI (N5 5), musculo-skeletal (N5 4), liver (N5 2),
genital (N5 2) and lung (N5 2). Median KPS was 80%. 7 subjects
required dose-reductions for muscle cramps, tremors and/or fatigue.
There was no bonemarrow suppression, neuropathy, somnolence or
thrombosis. 5 subjects discontinued therapy: 1 for worsening skin
andmouth lesions, 3 for no response (2 had worsening tremors, mus-
cle cramps and fatigue) and 1 for worsening pain. 1 subject died of
a heart attack 4 m after stopping POM. 3 subjects completed 6 m
of therapy and underwent 2nd response evaluation: 2 at 2 mg/d
and 1 at 1 mg/d. 2 have a complete response (CR) and 1 a partial re-
sponse (PR) of erythematous skin changes and aCR ofGI symptoms.There are ongoing improvements\PR in skin, mouth, and eyes. 3
subjects have a global PR.
Conclusion: POM can be given for corticosteroid-resistant
cGVHD without toxicities that limit use of thalidomide in this
context. Our data suggest POM is active in moderate/severe corti-
costeroid-resistant cGVHD. 3 mg/d is likely a too high starting
dose: we recommend 1-2 mg/d in future studies. Subject accrual
continues, as do correlative laboratory studies; these data will be
reported.418
A PROSPECTIVE STUDY OF DONOR IMMUKNOW AS A BIOMARKER FOR
ACUTE GVHD IN HEMATOPOIETIC CELL TRANSPLANTATION RECIPIENTS
Kang, Y.1, DeOliveira, A.2, Peel, L.E.2, Chen, D.-F.2, Chao, N.1 1 Duke
University Medical Center, Durham, NC; 2 Duke University Medical
Center, Durham, NC
Introduction:Graft versus host disease (GvHD) occurs in40% of
allogeneic hematopoietic cell transplantation (HCT) recipients and
is associated with substantial morbidity and mortality. Immunolog-
ical parameters of donor cells that predispose a recipient to GvHD
will be of great value. The Cylex ImmuKnow assay determines
the strength of immune function by quantifying the amount of
ATP released from phytohemagglutinin-stimulated peripheral
bloodCD4+ cells. In our current study, we utilized the ImmuKnow
to assess whether a donor’s immune response correlates with early
outcomes in recipients post-HCT.
Patients and Methods: Twenty-six (26) donor-recipient pairs were
included in our study (15 HLA identical siblingHCT and 11 haploi-
dentical HCT). Recipients received an average cell-dose of
10.76 4.9  106 CD34+ cells/kg. Blood samples obtained prior to
G-CSFmobilization and prior to stem cell collection (approximately
2 weeks apart) were assayed for ImmuKnow values and cell counts
(WBC, ANC, ALC & CD34+ count).
Results:G-CSF mobilization led to a significant increase in Immu-
Know ATP values from 342 to 728 ng/mL (p\0.001) along with
an increase in all measured cell counts. Grade$ II acute GvHD oc-
curred in 27% of haploidentical HCT recipients (3/11 patients)
and 20% of HLA identical HCT recipients (3/15 patients). In hap-
loidentical HCT, mobilized donor blood ImmuKnow ATP
values did not correlate with GvHD. However, donor Immu-
Know values correlated with increased risk of acute GvHD in
HLA identical sibling HCT. In HLA identical sibling HCT,
ATP values in excess of 747 ng/mL predicted grade II or higher
GvHD with a likelihood ratio of 4.00 (2.9-5.5, 95% confidence),
sensitivity of 100%, and specificity of 75% (AUC5 0.889,
p5 0.003).
Conclusions: If confirmed in larger studies, these data suggest that
ImmuKnow can serve as an independent predictor/biomarker for the
development of GvHD in HLA identical HCT.419
MYCOPHENOLATE MOFETIL AS THERAPY FOR STEROID DEPENDENT OR
REFRACTORY GRAFT VERSUS HOST DISEASE: TEN YEARS EXPERIENCE
FROM A SINGLE CENTER IN BRAZIL
Nunes, E.C., Funke, V.A.M., Setubal, D.C., Medeiros, L.A.,
Oliveira, M.M., Bonamin, C., Nabhan, S., Bitencourt, M.A.,
Ribeiro, L., Morando, J., Bonfim, C., Vieira, A.G., Franco, V.,
Loth, G., Pasquini, R., Neto, J.Z. Hospital de Clinicas-Federal University
of Parana, Curitiba, Parana, Brazil
Chronic graft-versus-Host-Disease (GVHD) is observed in up to
50% of long term survivors of hematopoietic stem cell transplants
(HSCT) and is associated to important morbidity and mortality.
Mycophenolate Mofetil (MMF) has been used as therapy for refrac-
tory chronicGVHDwith good efficacy and tolerability.We describe
our experience at Hospital de clınicas of Federal University of Par-
ana-Brazil during the last ten years on the use of this drug as rescue
for refractory chronic GVHD.
